dc.contributor.author | Syndikus, I | |
dc.contributor.author | Cruickshank, C | |
dc.contributor.author | Staffurth, J | |
dc.contributor.author | Tree, A | |
dc.contributor.author | Henry, A | |
dc.contributor.author | Naismith, O | |
dc.contributor.author | Mayles, H | |
dc.contributor.author | Snelson, N | |
dc.contributor.author | Hassan, S | |
dc.contributor.author | Brown, S | |
dc.contributor.author | Porta, N | |
dc.contributor.author | Griffin, C | |
dc.contributor.author | Hall, E | |
dc.date.accessioned | 2020-10-12T09:54:57Z | |
dc.date.issued | 2020-11-01 | |
dc.identifier.citation | Clinical and translational radiation oncology, 2020, 25 pp. 22 - 28 | |
dc.identifier.issn | 2405-6308 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4137 | |
dc.identifier.eissn | 2405-6308 | |
dc.identifier.doi | 10.1016/j.ctro.2020.08.003 | |
dc.description.abstract | •PIVOTALboost evaluates benefits/toxicity of pelvic node RT and focal boost dose escalation.•Unfavourable intermediate/high risk and bulky local disease are most likely to benefit.•Functional MRI imaging is used to select patients for different types of dose escalation.•HDR brachytherapy or focal dose escalation with IMRT are used as options.•Training and support is provided to reduce variations of contouring and radiotherapy planning.•The trial is recruiting patients in 38 radiotherapy centres through the UK. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 22 - 28 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER IRELAND LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-08-24 | |
rioxxterms.versionofrecord | 10.1016/j.ctro.2020.08.003 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical and translational radiation oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.publication-status | Published | |
pubs.volume | 25 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
icr.researchteam | ICR-CTSU Urology and Head and Neck Trials Team | |
dc.contributor.icrauthor | Cruickshank, Clare | |
dc.contributor.icrauthor | Brown, Stephanie | |
dc.contributor.icrauthor | Porta, Nuria | |
dc.contributor.icrauthor | Griffin, Clare | |
dc.contributor.icrauthor | Hall, Emma | |